Erste Asset Management GmbH Buys Shares of 50,000 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Erste Asset Management GmbH purchased a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,000 shares of the company's stock, valued at approximately $360,000. Erste Asset Management GmbH owned approximately 0.07% of EyePoint Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also modified their holdings of EYPT. Swiss National Bank increased its position in shares of EyePoint Pharmaceuticals by 3.5% in the 4th quarter. Swiss National Bank now owns 100,000 shares of the company's stock valued at $745,000 after purchasing an additional 3,400 shares during the last quarter. AlphaQuest LLC increased its position in shares of EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after purchasing an additional 9,670 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at about $76,000. Charles Schwab Investment Management Inc. boosted its position in shares of EyePoint Pharmaceuticals by 33.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 191,165 shares of the company's stock valued at $1,424,000 after purchasing an additional 48,402 shares during the period. Finally, Levin Capital Strategies L.P. grew its stake in EyePoint Pharmaceuticals by 440.0% during the 4th quarter. Levin Capital Strategies L.P. now owns 54,000 shares of the company's stock worth $402,000 after buying an additional 44,000 shares during the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.

Remove Ads

EyePoint Pharmaceuticals Price Performance

NASDAQ EYPT traded down $0.02 on Wednesday, hitting $6.19. 986,326 shares of the company's stock were exchanged, compared to its average volume of 865,393. The firm has a market cap of $425.43 million, a price-to-earnings ratio of -3.10 and a beta of 1.41. The firm's 50-day moving average price is $7.09 and its two-hundred day moving average price is $8.35. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $5.54 and a fifty-two week high of $23.97.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The business had revenue of $11.60 million during the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EYPT. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, EyePoint Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.